The study’s goal was to see if the incidence of infusion responses (IR) in children increased following fast infliximab (IFX) infusions vs normal infusions. A systematic evaluation of papers documenting the number of IR following fast IFX infusion in children aged 0 to 18 years was conducted. There were four records featured. The reported occurrences of IR varied from 0% to 2% of infusions in regular groups and from 0% to 2% of infusions in fast groups. There was no significant difference in the incidence of IR between the two groups, according to any of the studies examined.

There is inadequate evidence to establish if the rate of IR rises following fast IFX. The constant finding of no increase in IR in all investigations, as well as the low rate of observed IR, implies that there is no substantial change in IR rate.

Reference: https://journals.lww.com/jpgn/Fulltext/2020/09000/Safety_of_Rapid_Infliximab_Infusions_in_Children_.14.aspx